HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO.
ABRYSVO (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use Initial U.S. Approval: 2023 RECENT MAJOR CHANGESIndications and Usage (1.1) | 8/2023 | Dosage and Administration (2.2) | 3/2024 | Warnings and Precautions (5.1) | 8/2023 |
INDICATIONS AND USAGEABRYSVO is a vaccine indicated for - •
- Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. (1.1)
- •
- Active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. (1.2)
DOSAGE AND ADMINISTRATION- •
- For intramuscular use. (2)
- •
- After reconstitution, a single dose of ABRYSVO is either approximately 0.5 mL (vial and prefilled syringe presentation) or 0.5 mL (vial and vial presentation). (2.1)
DOSAGE FORMS AND STRENGTHSFor injection. For the vial and prefilled syringe presentation, a single dose after reconstitution is approximately 0.5 mL. (3) For the vial and vial presentation, a single dose after reconstitution is 0.5 mL. (3) CONTRAINDICATIONSHistory of severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO. (4) WARNINGS AND PRECAUTIONS- •
- Potential risk of preterm birth. To avoid the potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer ABRYSVO as indicated in pregnant individuals at 32 through 36 weeks gestational age.
ADVERSE REACTIONS- •
- The most commonly reported solicited local and systemic adverse reactions in pregnant individuals (≥10%) were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%). (6.1)
- •
- The most commonly reported solicited local and systemic adverse reactions in individuals 60 years of age and older (≥10%) were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%). (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov. See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2024 |